中证报中证网讯(记者黄一灵)1月27日，先声药业公告称，旗下附属公司1月26日与全球生物制药公司勃 林格殷格翰签署独家授权许可协议，勃林格殷格翰将获得用于炎症性肠病的TL1A/IL-23p19双特异性抗 体SIM0709在大中华区以外的全球独家权益。 据悉，本次合作是先声药业在自身免疫疾病领域的第2个创新药海外授权项目，也是公司第5个实现对外 技术授权许可的自研创新药早研项目，截至目前公司潜在交易总金额累计已超过46亿美元。近年来，先 声药业持续加大研发投入，与此同时，公司创新药收入占比从2020年的45%提升至2025年上半年的 77%。 根据该协议条款，先声药业有权收取4200万欧元的首付款，以及基于研发进展、监管审批及商业化等情 况，最高达10.16亿欧元的里程碑付款。此外，先声药业亦有权就大中华区以外的净销售额收取分级特 许权使用费。 "SIM0709由先声药业多抗技术平台开发，在炎症性肠病治疗领域具有'同类首创'潜力。勃林格殷格翰在 全球免疫治疗领域多年来积淀深厚，相信本次合作将为该分子的全球开发奠定坚实基础。"先声药业首 席投资官周高波表示。 ...

2026.01. 24 本文字数：3320，阅读时长大约5分钟 作者 | 第一财经 彭海斌 2026年，中国新药出海热度不减。 1月尚未结束，中国药企已经完成10笔海外授权交易，其中荣昌生物和艾伯维的交易首付款达到6.5亿 美元。 首付款超过一级市场融资 2025年1月，先为达与英国企业Verdiva Bio Limited达成合作。 先为达是一家开发糖尿病及减重药物的中国企业。它将正在临床阶段的口服伊诺格鲁肽等授予后者大 中华区和韩国以外的开发权利。这笔交易的首付款约7000万美元，且可获得最高达24亿美元的潜在 开发、注册和商业化里程碑付款，以及产品商业化后的销售额提成。 先为达商业战略副总经理鲍恺军对第一财经记者说，Verdiva的二期临床试验会先在美国开展，试验 方案已经基本敲定了。 最近两年，代谢领域的授权交易升温。2025年，中国药企发生了七笔对外授权。这很大程度上源于 礼来和诺和诺德在减重药物市场取得的令人瞩目的成功。礼来更是成为全球首家市值突破一万亿美元 的医药公司，与英伟达、苹果、谷歌等科技巨头并肩而立。 中国代谢领域的交易，是2025年创新药海外授权爆发性增长的缩影。 据医药魔方统计，20 ...

Group 1 - ST Lingnan held its 36th meeting of the fifth board of directors on October 24, 2025, to discuss a proposal to sue the former controlling shareholder [1] - For the first half of 2025, ST Lingnan's revenue composition was as follows: Ecological landscaping accounted for 43.99%, water and environmental management business for 41.94%, and cultural tourism for 14.07% [1] - As of the report, ST Lingnan's market capitalization was 3.4 billion yuan [1] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year [1] - There is a contrast between the hot secondary market for biomedicine and the cooling fundraising environment in the primary market [1]

Group 1 - The core point of the article is that Tianmai Technology (SZ 300807) held its 13th board meeting on October 24, 2025, to review the agenda including the third-quarter report for 2025 [1] - For the year 2024, Tianmai Technology's revenue composition is entirely from intelligent transportation, accounting for 100.0% [1] - As of the report, Tianmai Technology has a market capitalization of 2.7 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated 80 billion USD in overseas licensing this year [1] - There is a discussion on the hot secondary market for biomedicine, while the primary market is facing challenges in fundraising [1]

Group 1 - Northern Copper Industry held its 10th fifth board meeting on October 24, 2025, via telecommunication to review the Q3 2025 report and other documents [1] - For the first half of 2025, Northern Copper's revenue composition was entirely from non-ferrous metal smelting and rolling processing, accounting for 100.0% [1] Group 2 - As of the report, Northern Copper's market capitalization is 30.3 billion yuan [2]

Group 1 - Company Hasi Lian reported a revenue of approximately 581 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 30.75% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 209 million yuan, with a basic earnings per share loss of 0.66 yuan [1] - The current market capitalization of Hasi Lian is 4.5 billion yuan [2] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion US dollars this year [2] - The secondary market for biomedicine is experiencing a boom, while the primary market is facing challenges in fundraising [2]

Group 1 - The core point of the article is that Changjiang Chenda, a major shareholder of Shangtai Technology, plans to reduce its stake in the company by selling up to 5,193,925 shares within three months after a 15 trading day notice period [1] - As of the announcement, Changjiang Chenda holds approximately 19.46 million shares, representing 7.4633% of the total share capital of Shangtai Technology [1] - Shangtai Technology's revenue composition for the first half of 2025 indicates that lithium-ion battery anode materials account for 91.57% of its revenue, while carbon products and other businesses contribute 4.81% and 3.62%, respectively [1] Group 2 - The current market capitalization of Shangtai Technology is 22.1 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion USD this year, indicating a hot secondary market for biomedicine [2]

Group 1 - Canaan Intelligent (SZ 300880) held its 19th meeting of the third board of directors on October 23, 2025, to review the proposal for the election of non-independent directors [1] - For the year 2024, Canaan Intelligent's revenue composition is entirely from the electrical instrumentation industry, accounting for 100.0% [1] - As of the report date, Canaan Intelligent has a market capitalization of 3.7 billion yuan [1] Group 2 - In 2023, China's innovative pharmaceuticals have generated $80 billion in overseas licensing deals [1] - The secondary market for biomedicine is experiencing a surge, while the primary market is facing challenges in fundraising [1]

Group 1 - The core point of the article is that Jianyou Co., Ltd. (SH 603707) held its 15th meeting of the 5th board of directors on October 24, 2025, to review the proposal for the company's Q3 2025 report [1] - For the year 2024, Jianyou Co., Ltd.'s revenue composition is 99.85% from the pharmaceutical manufacturing industry and 0.15% from other businesses [1] - As of the report date, Jianyou Co., Ltd. has a market capitalization of 15.6 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year [1] - It highlights a conversation with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while the primary market faces fundraising challenges [1]

Group 1 - The core point of the article is that Nuo Wei Co., Ltd. held its 33rd meeting of the fifth board of directors on October 24, 2025, to review the proposal for the third quarter report of 2025 [1] - For the year 2024, the revenue composition of Nuo Wei Co., Ltd. is 99.29% from industrial valves and 0.71% from other businesses [1] - As of the report date, the market capitalization of Nuo Wei Co., Ltd. is 34.5 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion US dollars this year [1] - There is a discussion about the hot secondary market for biomedicine, while the primary market is facing challenges in fundraising [1]